Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
Lexeo Therapeutics (Nasdaq: LXEO) will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 10:00 a.m. ET in Miami, FL.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lexeo Therapeutics (Nasdaq: LXEO) will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 10:00 a.m. ET in Miami, FL.
The presentation will be webcast live via the company's Investors & News & Events page, with a replay available on the Lexeo website after the session.
Details
News Market Reaction – LXEO
On Mar 3, the day this news came out, LXEO closed 0.84% below the previous close.
Data tracked by StockTitan Argus for the Mar 3 session.
Key Figures
- Conference date
- March 10, 2026
- Leerink Global Healthcare Conference fireside chat
- Conference time
- 10:00 a.m. ET
- Scheduled time for Leerink fireside chat
- Webcast access
- Live + replay
- Available under News & Events on investor website
Historical Context
-
Announcement of management participation in two February 2026 investor conferences.
-
Senior leadership appointments and update to strategic cardiac RNA partnership.
-
Positive interim Phase I/II HEROIC-PKP2 data for LX2020 in cardiomyopathy.
-
Collaboration with Johnson & Johnson on targeted cardiac AAV gene delivery.
-
Planned CEO presentation at the 44th Annual J.P. Morgan Healthcare Conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 10:00 a.m. ET in Miami, FL.
The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy, LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Media Response:
Media@lexeotx.com
Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.